Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a strong and wide ...

As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are targeting the next goalpost: a cure.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you ...

Gilead gave the money to doctors who spoke at HIV Speaker Program events in the form of honoraria payments, meals and travel expenses, according to the U.S. Attorney's Office in Manhattan ...

Gilead Sciences (NasdaqGS:GILD) recently announced positive results from its ASCENT-03 study, leading to a significant role ...

The global HIV market is expected to reach $32.1 billion by 2033, driven by long-acting injectables and innovative therapies, ...

Global health leaders called for the Pandemic Agreement adopted at the 78th World Health Assembly to deliver where past efforts failed—equitable access to life-saving technologies and services during ...

Everyone who wants a new HIV shot* should be given it, according to Yvette Raphael, who chaired the Global Community Advisory Group for the large-scale clinical trials of the long-acting HIV treatment ...